Valerie Aponte Ribero

Valerie Aponte Ribero

Auto-generated profile, based on publicly available information

Valerie Aponte Ribero

Institute of Primary Health Care (BIHAM), University of Bern Bern Switzerland

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 November 2023 in Neurology
Verified
Journal Article
Open access
PDF file
VRValerie Aponte Ribero
Valerie Aponte Ribero
YMYasmina Martí
Yasmina Martí
SBSarah Batson
Sarah Batson
SMStephen Mitchell
Stephen Mitchell
KGKsenija Gorni
Ksenija Gorni
CSC. Simone Sutherland
C. Simone Sutherland
Background and Objectives Spinal muscular atrophy (SMA) is a progressive neuromuscular disorder associated with continuous motor function loss and complications such as scoliosis and contractures. Understanding the natural history of SMA is key to demonstrating the long-term outcomes of SMA treatments. This study reviews the natural history of motor function, scoliosis, and contractures in patients with SMA. Methods Electronic databases were searched from inception to June 27, 2022 (Embase, MEDLINE, and Evidence-Based Medicine Reviews). Observational studies, case–control studies, cross-sectional studies, and case series reporting on motor function (i.e., sitting, standing, and walking ability), scoliosis, and contracture outcomes in patients with Types 1–3 SMA were included. Data on study design, baseline characteristics, and treatment outcomes were extracted. Datasets were generated from studies that reported Kaplan–Meier (KM) curves and pooled to generate overall KM curves. Results Ninety-three publications were included, of which 68 reported on motor function. Of these, 10 reported KM curves (three on the probability of sitting in patients with Types 2 and 3 SMA, and eight on the probability of walking/ambulation in patients with Type 3 SMA). The median time to loss of sitting (95% confidence interval [CI]) was 14.5 years (14.1–31.5) for the Type 2 SMA sitter population (their maximum ability was independent sitting). The median time to loss of ambulation (95% CI) was 13.4 years (12.5–14.5) for Type 3a SMA (disease onset at age <3 years) and 44.2 years (43.0–49.4) for Type 3b SMA (disease onset at age ≥3 years). Studies including scoliosis and contracture outcomes mostly reported non-time-to-event data. Discussion Results demonstrate that a high degree of motor function loss is inevitable, affecting patients of all ages. Additionally, data suggest that untreated patients with Types 2 and 3 SMA remain at risk of losing motor milestones during late adulthood, and patients with Types 3a and 3b SMA are at risk of loss of ambulation over time. These findings support the importance of stabilization of motor function development even at older ages. Natural history data are key for the evaluation of SMA treatments as they contextualize the assessment of long-term outcomes.

1 April 2022 in Journal of Comparative Effectiveness Research
Verified
Journal Article
Open access
VRValerie Aponte Ribero
Valerie Aponte Ribero
MDMonica Daigl
Monica Daigl
YMYasmina Martí
Yasmina Martí
KGKsenija Gorni
Ksenija Gorni
RERachel Evans
Rachel Evans
NHNeil Hawkins
Neil Hawkins
Aim: To conduct indirect treatment comparisons between risdiplam and other approved treatments for spinal muscular atrophy (SMA). Patients & methods: Individual patient data from risdiplam trials were compared with aggregated data from published studies of nusinersen and onasemnogene abeparvovec, accounting for heterogeneity across studies. Results: In Type 1 SMA, studies of risdiplam and nusinersen included similar populations. Indirect comparison results found improved survival and motor function with risdiplam versus nusinersen. Comparison with onasemnogene abeparvovec in Type 1 SMA and with nusinersen in Types 2/3 SMA was challenging due to substantial differences in study populations; no concrete conclusions could be drawn from the indirect comparison analyses. Conclusion: Indirect comparisons support risdiplam as a superior alternative to nusinersen in Type 1 SMA.

28 October 2024 in European Journal of Clinical Investigation
Verified
Journal Article
Open access
VRValerie Aponte Ribero
Valerie Aponte Ribero
OEOrestis Efthimiou
Orestis Efthimiou
NANazanin Abolhassani
Nazanin Abolhassani
HAHeba Alwan
Heba Alwan
DBDouglas C. Bauer
Douglas C. Bauer
BGBaris Gencer
Baris Gencer
Background: Guidelines and studies provide conflicting information on whether type 2 diabetes (T2D) should be considered a coronary heart disease risk (CHD) equivalent in older adults.Methods: We synthesized participant‐level data on 82,723 individuals aged ≥65 years from five prospective studies in two‐stage meta‐analyses. We estimated multivariable‐adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) of T2D (presence versus absence) on a primary composite outcome defined as cardiovascular events or all‐cause mortality. Secondary outcomes were the components of the composite. We evaluated CHD risk equivalence by comparing outcomes between individuals with T2D but no CHD versus CHD but no T2D.Results: The median age of participants was 71 years, 20% had T2D and 17% had CHD at baseline. A total of 29,474 participants (36%) experienced the composite outcome. Baseline T2D was associated with higher risk of cardiovascular events or all‐cause mortality versus no T2D (HR 1.44, 95% CI [1.40–1.49]). The association was weaker in individuals aged ≥75 years versus 65–74 years (HR 1.32 [1.19–1.46] vs. 1.56 [1.50–1.62]; p‐value for interaction = .032). Compared to individuals with CHD but no T2D, individuals with T2D but no CHD had a similar risk of the composite outcome (HR 0.95 [0.85–1.07]), but a lower risk of cardiovascular events (HR 0.76 [0.59–0.98]).Conclusions: T2D was associated with increased risk of cardiovascular events and all‐cause mortality in older adults, but T2D without CHD conferred lower risk of cardiovascular events compared to CHD without T2D. Our results suggest that T2D should not be considered a CHD risk equivalent in older adults.

30 September 2025 in European Journal of Clinical Investigation
Verified
Journal Article
Open access
VRValerie Aponte Ribero
Valerie Aponte Ribero
OBOliver Baretella
Oliver Baretella
CGCinzia Del Giovane
Cinzia Del Giovane
MHMoa Haller
Moa Haller
MFMartin Feller
Martin Feller
NRNicolas Rodondi
Nicolas Rodondi
Background: The benefit of statins in multimorbid older adults is controversial. Prior observational studies evaluating statin discontinuation in older adults were retrospective cohorts, did not focus on multimorbidity, or lacked adjustment for geriatric syndromes. We aimed to assess the effect of statin discontinuation on cardiovascular and mortality outcomes using the target trial emulation framework. Methods: We conducted a prospective cohort study using data from the OPERAM trial in adults aged ≥70 years with ≥3 chronic conditions and ≥5 chronic drugs, comparing statin discontinuation to continuation. The primary composite outcome was cardiovascular events or all‐cause mortality at 12 months. We calculated adjusted hazard ratios (HR) using weighted pooled logistic regressions without (model‐A) and with adjustment for two geriatric syndromes (falls and weight loss; model‐B). Results: Of 2668 person‐trial units (mean age 78.5 years), 2533 (95%) continued and 133 (5%) discontinued statins. Discontinuation was associated with higher composite outcome risk (27% vs. 18%; HR model‐A 1.53 [95% CI 1.14–2.06]; model‐B 1.49 [1.12–1.99]). This was mainly attributable to increased non‐cardiovascular deaths (20% vs. 11%; HR model‐A 1.56 [1.08–2.27]; model‐B 1.52 [1.06–2.19]); there was no clear evidence for an association with cardiovascular events (7% vs. 8%; HR model‐A 1.36 [.86–2.14]; model‐B 1.35 [.86–2.12]). Conclusion: In this first target trial emulation in a multimorbid older population, statin discontinuation was associated with increased risk of the composite of cardiovascular events or all‐cause mortality, primarily driven by non‐cardiovascular deaths. Geriatric syndromes did not modify these increased risks. Only clinical trials can clarify the safety of statin discontinuation.

14 May 2025 in European Journal of Preventive Cardiology
Verified
Journal Article
Open access
VRValerie Aponte Ribero
Valerie Aponte Ribero
OEOrestis Efthimiou
Orestis Efthimiou
HAHeba Alwan
Heba Alwan
DBDouglas C Bauer
Douglas C Bauer
SHSéverine Henrard
Séverine Henrard
BGBaris Gencer
Baris Gencer
Aims: No cardiovascular risk prediction model dedicated to individuals aged ≥70 years with diabetes is currently recommended by the European Society of Cardiology. We aimed to develop a new model, CArdiovascular Risk Estimation—Diabetes Mellitus (CARE-DM), to predict the risk of cardiovascular disease (CVD) in older adults with type 2 diabetes. Methods and results: We developed a model to predict the risk of incident CVD in participants aged ≥65 years with diabetes using data from four population-based prospective cohorts, accounting for the competing risk of non-cardiovascular death. Pre-specified predictors were age, gender, smoking status, alcohol consumption, body mass index, total and HDL cholesterol, use of antihypertensive, cholesterol-lowering and glucose-lowering medication, diabetes duration, and glycated haemoglobin. We assessed model performance using measures of calibration and discrimination. We used a 10-fold cross-validation and a bootstrapping approach to correct estimates for optimism and conducted an internal–external cross-validation. A total of 6943 participants (median age 72 years, 56% women) with diabetes were included in the model development. Over a median follow-up of 6.3 (interquartile range 3.7, 7.2) years, 1204 (17.3%) participants experienced a CVD event. Internal validation with optimism correction showed adequate model performance with a C-index of 0.65 (95% confidence interval 0.63–0.67), an observed-to-expected ratio of 1.01 (0.95–1.08), and a calibration slope of 1.13 (0.95–1.31) at 5 years. Conclusion: The new CARE-DM model allows prediction of the incident CVD risk in older adults with type 2 diabetes. Independent external validation should be conducted to confirm the model’s performance before implementation in clinical practice.

13 March 2023 in medRxiv
Verified
Preprint
Open access
PDF file
VRValerie Aponte Ribero
Valerie Aponte Ribero
HAHeba Alwan
Heba Alwan
OEOrestis Efthimiou
Orestis Efthimiou
NANazanin Abolhassani
Nazanin Abolhassani
DBDouglas C Bauer
Douglas C Bauer
CGCinzia Del Giovane
Cinzia Del Giovane
Introduction Older and multimorbid adults with type 2 diabetes (T2D) are at high risk of cardiovascular disease (CVD) and chronic kidney disease (CKD). Estimating risk and preventing CVD is a challenge in this population notably because it is underrepresented in clinical trials. Our study aims to (1) assess if T2D and haemoglobin A1c (HbA1c) are associated with the risk of CVD events and mortality in older adults, (2) develop a risk score for CVD events and mortality for older adults with T2D, (3) evaluate the comparative efficacy and safety of novel antidiabetics. Methods and analysis For Aim 1, we will analyse individual participant data on individuals aged ≥65 years from five cohort studies: the Optimising Therapy to Prevent Avoidable Hospital Admissions in Multimorbid Older People study; the Cohorte Lausannoise study; the Health, Aging and Body Composition study; the Health and Retirement Study; and the Survey of Health, Ageing and Retirement in Europe. We will fit flexible parametric survival models (FPSM) to assess the association of T2D and HbA1c with CVD events and mortality. For Aim 2, we will use data on individuals aged ≥65 years with T2D from the same cohorts to develop risk prediction models for CVD events and mortality using FPSM. We will assess model performance, perform internal-external cross validation, and derive a point-based risk score. For Aim 3, we will systematically search randomized controlled trials of novel antidiabetics. Network meta-analysis will be used to determine comparative efficacy in terms of CVD, CKD, and retinopathy outcomes, and safety of these drugs. Confidence in results will be judged using the CINeMA tool. Ethics and dissemination Aims 1 and 2 were approved by the local ethics committee (Kantonale Ethikkommission Bern); no approval is required for Aim 3. Results will be published in peer-reviewed journals and presented in scientific conferences. STRENGTHS AND LIMITATIONS We will analyse individual participant data from multiple cohort studies of older adults who are often not well represented in large clinical trials. By using flexible survival parametric models, we will be able to capture the potentially complex shapes of the baseline hazard functions of cardiovascular disease (CVD) and mortality. Our network meta-analysis will include recently published randomised controlled trials on novel anti-diabetic drugs that have not been included in previous network meta-analysis and results will be stratified by age and baseline HbA1c Although we plan to use several international cohorts, the external validity of our findings and particularly of our prediction model will need to be assessed in independent studies Our study will help guide CVD risk estimation and prevention among older adults with type 2 diabetes